Documenti analoghi

• Genetics of Response to Canagliflozin ( GRC ) Study: Rationale, Design, and Pharmacodynamic Responses
  di: May E. Montasser, et al.
  Pubblicazione: (2026)
• Randomized evaluation of the loss‐of‐function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics
  di: Joshua P. Lewis, et al.
  Pubblicazione: (2024)
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design
  di: Sibel Ucpinar, et al.
  Pubblicazione: (2024)
• Correction to “Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects”
  Pubblicazione: (2024)
• Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
  di: Pratik Bhagunde, et al.
  Pubblicazione: (2026)